Atai Life Sciences N.V. (ATAI)
NASDAQ: ATAI · IEX Real-Time Price · USD
1.480
0.00 (0.00%)
At close: Jul 19, 2024, 4:00 PM
1.520
+0.040 (2.70%)
Pre-market: Jul 22, 2024, 7:05 AM EDT
Atai Life Sciences Revenue
Atai Life Sciences had revenue of $277.00K in the twelve months ending March 31, 2024, with 2.97% growth year-over-year. In the year 2023, Atai Life Sciences had annual revenue of $314.00K with 34.76% growth.
Revenue (ttm)
$277.00K
Revenue Growth
+2.97%
P/S Ratio
894.44
Revenue / Employee
$3,337
Employees
83
Market Cap
247.76M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 314.00K | 81.00K | 34.76% |
Dec 31, 2022 | 233.00K | -20.14M | -98.86% |
Dec 31, 2021 | 20.38M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Codexis | 74.23M |
AVITA Medical | 51.50M |
Utah Medical Products | 49.04M |
Nanobiotix | 40.23M |
Zevra Therapeutics | 28.01M |
Senseonics Holdings | 23.30M |
Profound Medical | 5.33M |
Immutep | 4.58M |
ATAI News
- 26 days ago - atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference - GlobeNewsWire
- 4 weeks ago - atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a - GlobeNewsWire
- 7 weeks ago - atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference - GlobeNewsWire
- 2 months ago - atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates - GlobeNewsWire
- 3 months ago - atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression - GlobeNewsWire
- 3 months ago - atai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of Psychopharmacology - GlobeNewsWire
- 4 months ago - atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights - GlobeNewsWire
- 4 months ago - atai Life Sciences Announces Positive Initial Results from Beckley Psytech's Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression - GlobeNewsWire